臨床検査62巻11号

2018年11月発行

今月の特集1 循環癌細胞（CTC）とリキッドバイオプシー

固形癌を対象としたリキッドバイオプシーの臨床応用

著者： 西尾和人¹ 坂井和子¹

所属機関： ¹近畿大学医学部ゲノム生物学

ページ範囲：P.1451 - P.1458

Point

●循環腫瘍DNA（ctDNA）は，デジタルPCRや次世代シークェンサー（NGS）を用いて分子プロファイリングが可能である．

●リキッドバイオプシー（LB）は，治療効果予測，治療経過中のモニタリングツールとして，その臨床的有用性が示されている．

●肺癌EGFR遺伝子変異検査の血漿検査が承認され，用いられている．

参考文献

1）Takahama T, Sakai K, Takeda M, et al：Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). Oncotarget　7：58492-58499，2016

2）Matsuo N, Azuma K, Sakai K, et al：Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. Sci Rep　6：36458，2016

3）Ohira T, Sakai K, Matsubayashi J, et al：Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer. Cancer Sci　107：1660-1666，2016

4）Takano T, Tsurutani J, Takahashi M, et al：A randomized phase Ⅱ trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Breast　40：67-75，2018

5）Sakai H, Tsurutani J, Iwasa T, et al：HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Breast Cancer 25：1-9，2018

6）Diaz LA Jr, Williams RT, Wu J, et al：The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature　486：537-540，2012

7）Shitara K, Yonesaka K, Denda T, et al：Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Cancer Sci　107：1843-1850，2016

8）Sakai K, Tsurutani J, Yamanaka T, et al：Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. PLoS One　10：e0121891，2015

9）Chabon JJ, Simmons AD, Lovejoy AF, et al：Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun　7：11815，2016

10）Iwama E, Sakai K, Azuma K, et al：Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations. Ann Oncol　28：136-141，2017